BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6356903)

  • 1. Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial.
    Wallin JD; Wilson D; Winer N; Maronde RF; Michelson EL; Langford H; Maloy J; Poland M
    Am J Med; 1983 Oct; 75(4A):87-94. PubMed ID: 6356903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension.
    Michelson EL; Frishman WH; Lewis JE; Edwards WT; Flanigan WJ; Bloomfield SS; Johnson BF; Lucas C; Freis ED; Finnerty FA
    Am J Med; 1983 Oct; 75(4A):68-80. PubMed ID: 6356901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy with labetalol in the treatment of mild hypertension: a double-blind study.
    Davidov ME; Moir GD; Poland MP; Maloy J; Medakovic M
    Am J Med; 1983 Oct; 75(4A):47-53. PubMed ID: 6356899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Step II treatment with labetalol for essential hypertension.
    Bloomfield SS; Lucas CP; Gantt CL; Poland MP; Medakovic M
    Am J Med; 1983 Oct; 75(4A):81-6. PubMed ID: 6356902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension.
    Frishman WH; Michelson EL; Johnson BF; Poland MP
    Am J Med; 1983 Oct; 75(4A):54-67. PubMed ID: 6356900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
    Easterling T; Mundle S; Bracken H; Parvekar S; Mool S; Magee LA; von Dadelszen P; Shochet T; Winikoff B
    Lancet; 2019 Sep; 394(10203):1011-1021. PubMed ID: 31378394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies.
    Wilson DJ; Wallin JD; Vlachakis ND; Freis ED; Vidt DG; Michelson EL; Langford HG; Flamenbaum W; Poland MP
    Am J Med; 1983 Oct; 75(4A):95-102. PubMed ID: 6139020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of methyldopa and labetalol in the treatment of hypertension.
    Sanders GL; Davies DM; Gales GM; Rao JG; Rawlins MD; Routledge PA
    Br J Clin Pharmacol; 1979; 8(Suppl 2):149S-151S. PubMed ID: 393286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labetalol, a cross-over double blind controlled trial.
    Sanders GL; Routledge PA; Rao JG; Gales GM; Davies DM; Rawlins MD
    Eur J Clin Pharmacol; 1978 Dec; 14(5):301-4. PubMed ID: 365543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group.
    Clin Pharmacol Ther; 1985 Jul; 38(1):24-7. PubMed ID: 2860990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study.
    Lechi A; Pomari S; Berto R; Buniotto P; Parrinello A; Marini F; Cogo L; Tomasi A; Baretta G
    Eur J Clin Pharmacol; 1982; 22(4):289-93. PubMed ID: 7049710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled comparison of the antihypertensive effects of labetalol and alpha-methyldopa.
    Al-Damluji SF; Al-Khalidi A; Shaarbaf H; Tawfiq NH
    Pharmatherapeutica; 1982; 3(2):133-9. PubMed ID: 7048338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol.
    Maronde RF; Robinson D; Vlachakis ND; Barr JW; Chung M; Zampaglione N; Medakovic M
    Am J Med; 1983 Oct; 75(4A):40-6. PubMed ID: 6356898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of labetalol and methyldopa in pregnancy-induced hypertension.
    Lamming GD; Symonds EB
    Br J Clin Pharmacol; 1979; 8(Suppl 2):217S-222S. PubMed ID: 526404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy.
    Rossi AG
    Clin Ther; 1981; 3(6):441-9. PubMed ID: 7260990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of labetalol and methyldopa on renal function.
    Cruz F; O'Neill WM; Clifton G; Wallin JD
    Clin Pharmacol Ther; 1981 Jul; 30(1):57-63. PubMed ID: 7237899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Labetalol in essential hypertension.
    Larochelle P; Hamet P; Hoffman B; Kuchel O; McKenzie J; Mitenko P; Ogilvie RI; Ruedy J
    J Cardiovasc Pharmacol; 1980; 2(6):751-9. PubMed ID: 6160325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response evaluation of oral labetalol in patients presenting to the emergency department with accelerated hypertension.
    Gonzalez ER; Peterson MA; Racht EM; Ornato JP; Due DL
    Ann Emerg Med; 1991 Apr; 20(4):333-8. PubMed ID: 2003657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.
    Ohman KP; Weiner L; von Schenck H; Karlberg BE
    Eur J Clin Pharmacol; 1985; 29(2):149-54. PubMed ID: 3908121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.